NIPER JEE key terms

The fraction of an administered dose of unchanged drug that reaches the systemic circulation, expressed as a percentage; intravenous dosing defines 100%, while oral values reflect absorption and first-pass loss.

Presystemic elimination of an orally absorbed drug by gut wall and liver enzymes before it enters systemic circulation, reducing oral bioavailability and often requiring higher oral than intravenous doses.

The integral of plasma drug concentration over time after a dose; it reflects total systemic exposure and is used to compute clearance, bioavailability, and bioequivalence comparisons.

The absence of a clinically significant difference in rate and extent of absorption between a test product and a reference product, usually shown by 90% confidence intervals of AUC and Cmax falling within 80–125%.

The volume of plasma from which a drug is completely removed per unit time; it determines the maintenance dose rate needed to sustain a target steady-state concentration.

An apparent volume relating the amount of drug in the body to its plasma concentration; a large value indicates extensive tissue distribution rather than confinement to blood.

The time required for plasma drug concentration to fall by half during first-order elimination; it governs dosing interval, time to steady state, and washout duration.

Elimination in which a constant amount of drug is removed per unit time regardless of concentration, because metabolic or transport pathways are saturated; half-life then lengthens as dose rises.

Capacity-limited, saturable metabolism described by maximum rate Vmax and affinity constant Km; at concentrations near or above Km, elimination shifts toward zero-order and drug accumulates disproportionately.

A safety ratio comparing the dose producing toxicity with the dose producing the desired effect; a narrow index demands therapeutic drug monitoring and careful dose titration.

Measurement of plasma drug concentrations to individualize dosing for drugs with narrow therapeutic ranges, poor concentration–effect predictability, or high interpatient pharmacokinetic variability.

A superfamily of heme-containing microsomal enzymes that oxidatively metabolize most drugs; specific isoforms mediate clinically important inhibition and induction interactions.

A pharmacologically inactive derivative converted in the body to an active agent, used to improve absorption, stability, taste, or targeting; conversion may depend on enzymatic or chemical hydrolysis.

Study of how inherited genetic variation, especially in drug-metabolizing enzymes, transporters, and targets, alters drug response and risk of adverse effects among individuals and populations.

Agonists bind receptors and activate them, while antagonists bind without intrinsic activity and block agonist effects; antagonist type (competitive or non-competitive) determines whether increasing agonist concentration can overcome blockade.

EC50 is the concentration producing half of a maximal response; IC50 is the concentration causing 50% inhibition. Both quantify potency and are read from concentration–response curves.

Internationally harmonized conditions for testing drug substance and product stability, specifying storage temperatures, humidity, and testing frequency for zone-classified climatic regions to establish shelf life.

Deliberate stressing of a drug with acid, base, oxidation, heat, or light to identify degradation products and prove that analytical methods are stability-indicating, i.e., able to separate degradants from the parent peak.

Documented demonstration that a method is suitable for its intended purpose, assessed through accuracy, precision, specificity, linearity, range, detection and quantitation limits, and robustness.

LOD is the lowest amount detectable but not reliably measurable; LOQ is the lowest amount that can be quantified with acceptable precision and accuracy, typically 3:1 and 10:1 signal-to-noise.

The separation achieved between two adjacent peaks, calculated from retention times and peak widths; a value of at least 1.5 indicates baseline separation adequate for reliable quantitation.

A separation technique in which a liquid mobile phase is pumped at high pressure through a packed column, resolving mixture components for identification and quantitative assay.

An analytical technique that ionizes molecules and separates them by mass-to-charge ratio, providing sensitive detection, molecular mass confirmation, and structural information when coupled to liquid chromatography.

Systematic detection and structural characterization of drug-derived products formed in vivo or in vitro, used to understand clearance pathways, reactive intermediates, and safety liabilities.

The systematic correlation between chemical structure modifications and observed biological activity, guiding rational design of more potent, selective, or safer analogues.

The medicinal chemistry phase that refines a validated hit into a development candidate by balancing potency, selectivity, pharmacokinetics, safety, and synthetic feasibility through iterative analogue design.

A heuristic predicting oral drug-likeness from molecular weight, lipophilicity (logP), hydrogen-bond donors, and acceptors; violations flag likely poor absorption or permeability.

Quantitative structure–activity relationship modeling uses computed molecular descriptors and statistical methods to predict biological activity or toxicity of untested compounds.

A computational method that predicts the preferred orientation and binding affinity of a ligand within a protein binding site, used to prioritize compounds before synthesis or testing.

The spatial arrangement of chemical features (hydrogen-bond donors and acceptors, hydrophobic groups, charged centers) required for a molecule to bind a target and produce activity.

A regulated quality system ensuring that medicinal products are consistently produced and controlled according to quality standards covering premises, personnel, documentation, validation, and complaint handling.

A systematic development approach that begins with predefined quality targets, identifies critical quality attributes and process parameters, and builds control strategy on understanding rather than end-product testing alone.

Documented evidence that a manufacturing process, operated within established parameters, reproducibly yields product meeting predetermined specifications; traditionally three consecutive successful batches, increasingly lifecycle-based.

A statistical approach to planning experiments that varies multiple factors simultaneously, revealing main effects and interactions efficiently and supporting robust formulation and process optimization.

A framework grouping drugs by aqueous solubility and intestinal permeability into four classes, used to justify biowaivers and anticipate absorption behavior of oral dosage forms.

A formulation that releases drug over an extended period to maintain plasma concentrations within therapeutic range, reducing dosing frequency and fluctuation while depending on consistent gastrointestinal transit.

The science of detecting, assessing, understanding, and preventing adverse effects or other drug-related problems, using spontaneous reports, signal detection, and risk management throughout a product's lifecycle.

A harmful, unintended response to a medicine at doses normally used for prophylaxis, diagnosis, or therapy, classified by mechanism (type A predictable, type B idiosyncratic) and by causality assessment.

A prospective study in which participants are randomly allocated to intervention or control groups, minimizing selection bias and supporting causal inference about treatment effect.

Analysis that includes all randomized participants in their assigned groups regardless of adherence or withdrawal, preserving randomization and giving a conservative estimate of effectiveness.

Voluntary agreement by a competent person to participate in research or treatment after receiving and understanding information about purpose, procedures, risks, benefits, and alternatives.

An independent committee that reviews and approves research involving human subjects, ensuring ethical conduct, risk minimization, and protection of vulnerable participants before the study begins.

A natural products strategy in which chromatographic fractions are repeatedly tested in a biological assay, and only active fractions are carried forward, yielding the compound responsible for observed activity.

A natural compound not essential for basic growth but produced by organisms for ecological roles such as defense or signaling; many antibiotics, alkaloids, and terpenoids are of this type.

A naturally occurring, usually basic nitrogen-containing organic compound from plants or microorganisms, often pharmacologically potent, with examples including morphine, quinine, and vincristine.

A characteristic constituent of an herbal material or extract used for identification, quality control, or standardization, even when it is not the primary active ingredient.

Adjusting an extract to a defined content of one or more marker or active constituents, supported by validated analytical methods, to ensure batch-to-batch consistency and reproducible clinical performance.

Regulatory grouping of devices by risk into classes (for example I, II, III in many systems), determining the conformity assessment route, clinical evidence, and post-market obligations required.

The documented process by which a manufacturer demonstrates that a device meets applicable safety and performance requirements before market authorization, often involving a notified or accredited body.

Systematic collection and review of real-world data on a marketed product's performance and safety, used to detect new risks and trigger field safety corrective actions when needed.

Legal protection granting an inventor limited exclusive rights over an invention; in pharmaceuticals, patent terms and regulatory data or market exclusivity periods jointly determine the timing of generic entry.

A regulatory submission for a generic product that relies on the reference product's existing safety and efficacy data, requiring instead demonstration of pharmaceutical equivalence and bioequivalence.

Extending market protection by obtaining new patents or exclusivities on modifications of an existing product, such as new formulations or uses, rather than on a genuinely new medicine.

The application of economic evaluation to medicines, comparing costs and health outcomes of alternatives through cost-effectiveness, cost-utility, or cost-benefit analysis to inform reimbursement decisions.

A health outcome metric combining length of life with health-related quality of life on a 0–1 scale, allowing comparison of interventions across diseases in cost-utility analysis.

The period during which a product stored under labeled conditions retains its specification-assigned potency, purity, and appearance, established from stability data and extended only with supporting evidence.